X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GLENMARK PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GLENMARK PHARMA SANOFI INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 39.9 25.3 158.0% View Chart
P/BV x 8.6 4.0 217.6% View Chart
Dividend Yield % 1.0 0.3 343.3%  

Financials

 SANOFI INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
GLENMARK PHARMA
Mar-17
SANOFI INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,560993 459.2%   
Low Rs4,400729 603.3%   
Sales per share (Unadj.) Rs1,028.5325.5 315.9%  
Earnings per share (Unadj.) Rs129.039.3 328.2%  
Cash flow per share (Unadj.) Rs186.048.7 382.2%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.2 653.6%  
Book value per share (Unadj.) Rs753.6159.2 473.3%  
Shares outstanding (eoy) m23.03282.17 8.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.6 164.7%   
Avg P/E ratio x34.721.9 158.5%  
P/CF ratio (eoy) x24.117.7 136.1%  
Price / Book Value ratio x5.95.4 109.9%  
Dividend payout %52.75.1 1,036.0%   
Avg Mkt Cap Rs m103,174242,991 42.5%   
No. of employees `0003.613.0 27.9%   
Total wages/salary Rs m3,59216,408 21.9%   
Avg. sales/employee Rs Th6,537.77,083.9 92.3%   
Avg. wages/employee Rs Th991.41,265.4 78.4%   
Avg. net profit/employee Rs Th819.8855.1 95.9%   
INCOME DATA
Net Sales Rs m23,68691,857 25.8%  
Other income Rs m708374 189.5%   
Total revenues Rs m24,39492,230 26.4%   
Gross profit Rs m5,28120,367 25.9%  
Depreciation Rs m1,3132,644 49.7%   
Interest Rs m152,373 0.6%   
Profit before tax Rs m4,66115,724 29.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,6913,827 44.2%   
Profit after tax Rs m2,97011,088 26.8%  
Gross profit margin %22.322.2 100.6%  
Effective tax rate %36.324.3 149.1%   
Net profit margin %12.512.1 103.9%  
BALANCE SHEET DATA
Current assets Rs m15,67368,746 22.8%   
Current liabilities Rs m6,67827,027 24.7%   
Net working cap to sales %38.045.4 83.6%  
Current ratio x2.32.5 92.3%  
Inventory Days Days7685 89.4%  
Debtors Days Days2296 23.4%  
Net fixed assets Rs m8,09824,132 33.6%   
Share capital Rs m230282 81.6%   
"Free" reserves Rs m17,08844,643 38.3%   
Net worth Rs m17,35644,925 38.6%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m25,400117,639 21.6%  
Interest coverage x311.77.6 4,088.0%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.90.8 119.4%   
Return on assets %11.811.4 102.7%  
Return on equity %17.124.7 69.3%  
Return on capital %26.919.1 140.7%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14556,152 12.7%   
Fx outflow Rs m6,8468,084 84.7%   
Net fx Rs m29948,068 0.6%   
CASH FLOW
From Operations Rs m3,2266,574 49.1%  
From Investments Rs m-1,555-7,124 21.8%  
From Financial Activity Rs m-1,8185,432 -33.5%  
Net Cashflow Rs m-1471,992 -7.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 6.9 208.7%  
FIIs % 14.6 34.4 42.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   15,184 56,727 26.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS